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Abstract
Volatile organic compounds (VOCs) detected in human breath, urine, stool, sweat, saliva, and
blood result from metabolic processes in the body during health or disease. Using sophisticated
measurement systems, small amounts of these compounds can be detected in the above bodily
fluids. Multiple studies in adults and children have shown the potential of these compounds to
differentiate between healthy individuals and patients by detecting profiles of compounds in
non-invasively collected samples. However, the detection of biomarkers in VOCs from neonates is
particularly attractive due to the non-invasive nature of its approach, and its ability to track disease
progress by longitudinal sampling. In this work we have reviewed the literature on the use of VOCs
in neonates and identified areas for future work. Overview of VOCs and their usefulness as
metabolic signatures. Detailed review of studies on VOCs in neonates Learn about potential uses of
VOCs as derived from adult and paediatric studies. Examine current limitations and identify future
work. Detailed studies on VOCs involving neonatal patients including sick preterm infants and
term infants with specific morbidities are needed. These studies should collect longitudinal
samples using non-invasive methods for the detection of potential biomarkers. Underlying
metabolic processes need to be identified so that any therapeutic options can be clarified.
1. Introduction
Sick newborn infants admitted to a neonatal intens-
ive care unit (NICU) need close continuous monitor-
ing throughout the length of their stay. They are also
subjected to multiple phlebotomy episodes and other
invasive investigations for diagnostic and monitor-
ing purposes. These investigations are essential but
can result in pain and discomfort [1–3], and in iatro-
genic blood loss requiring blood transfusions [4, 5].
Long term impacts of neonatal care include mental
health problems, including phobias [6], whichmay be
related to their experiences as inpatients. The burden
of these problems are significant and the incidence of
NICU admissions is increasing in theUSA [7] and the
UK.
Invasive investigations in NICU for the dia-
gnosis of disease, monitoring disease progress, chan-
ging acute management, or determining prognosis
remain the gold standard for neonatal care. However,
advances in technology have enabled trials of point-
of-care tests [8, 9] and non-invasive options. Pulse
oximetry is an example of a universally used mon-
itoring device for sick infants [10] which provides
a continuous display of the cardio-respiratory status
of the patient. Transcutaneous monitoring of carbon
dioxide of infants on respiratory support can provide
a continuous trend analysis of respiratory status
© 2021 The Author(s). Published by IOP Publishing Ltd
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[11] and consequently reduce phlebotomy episodes
for blood gas analysis [12]. Transcutaneous biliru-
bin measurements for screening neonates has also
been in use for several years which also has poten-
tial for reducing invasive blood tests [13]. However,
another strategy to reduce invasive tests on neonates
includes the use of urine, stool and exhaled breath
as sources for volatile organic compounds (VOCs)
and metabolic end products, which may be useful as
biomarkers.
NICU patients experience a range of patho-
physiological processes including inflammation,
infection, genetic disorders, and other congenital
malformations, and often require mechanical or
pharmacological support. A combination of the
pathophysiology and the external support required
can often result in complex morbidities of multiple
organ systems like the lungs (bronchopulmonary dys-
plasia, pneumonia), gut (necrotising enterocolitis),
liver (hepatitis, cholestasis), bone (metabolic bone
disease), and brain (intraventricular haemorrhage,
periventricular leukomalacia) [14]. Currentlymost of
these conditions are diagnosed retrospectively using
static and invasive investigation methods, although
almost certainly they develop over time and involve
multiple metabolic processes. The ability to detect
themdynamically and non-invasively well before they
present clinically is an attractive proposition. Prime
candidates for such detection are the lung and gut
morbidities where breath, urine and stool samples
can be used to monitor disease-specific changes and
offer potentially mitigating therapeutics.
Numerous metabolic processes in the body pro-
duce end products which are dissolved in the blood
and are excreted by the lungs, kidneys, and bowel.
Excretion products from these organs include exhaled
breath, urine, and stool, carry signatures of these
metabolic end products in the form of VOCs. The
ability to recognise specific VOCs by smell as charac-
teristic signs of disease, like the sweet acetonic smell
of diabetic ketoacidosis, fishy breath related to liver
disease, the urine-like smell in patients of kidney fail-
ure, and the mousy/musty odour of patients with
untreated phenylketonuria, has been recognised for
a long time [15]. While these examples are attrib-
uted to specific metabolic products, thousands of
other compounds are detectable in exhaled breath
and other bodily fluids, leading to the development
of the term ‘volatilome’ to describe the study of com-
plex mixtures of VOCs from breath and body flu-
ids (as well as other areas of science like food pro-
cessing, plant biology, etc.). Using a combination of
highly sensitive techniques including gas chromato-
graphy (GC) and mass spectrometry (MS), the volat-
ilome from various body fluids has been used for the
detection of biomarkers. The aim of this work is to
systematically review of studies of VOC detection in
neonatal patients, their potential uses and how the use
of VOC diagnostics in adult and paediatric patients
may be applicable to the neonatal population. We
will also discuss the current limitations of these
diagnostic techniques and identify potential future
work.
2. Methods of detection and interpretation
A variety of systems and techniques have been
employed to analyse gas-phase VOCs from a range
of biological samples [15]. Gas chromatography–
mass spectroscopy (GC–MS) is considered the gold
standard technique, as it provides comprehensive
profiles of VOCs and allows quantitation of com-
pounds present within a sample. In combinationwith
sampling methods such as thermal desorption tubes
or solid phase microextraction, the method is highly
sensitive and can identify single VOCs, and thus
can allow identification of underlying metabolic pro-
cesses involved in its production and excretion. How-
ever, although sampling can be carried out in situ, the
actual analysis needs to be carried out off-site as the
equipment required is bulky. GC–MS systems are also
relatively expensive and require highly trained operat-
ors, and thismeans that it is challenging to implement
GC–MS based methods as a routine diagnostic tool.
Sampling is also intermittent and discontinuous; the
method is, therefore, not suited to detect compounds
in real-time.
In the efforts to create a more practical method
of detection for clinical use, ‘electronic nose’ tech-
nology has been developed. These instruments do
not detect and identify specific compounds present
within a sample, rather attempt to identify patterns
of chemicals using an array of non-specific detect-
ors. Electronic noses can have an array of anywhere
between 8 and 32 sensors that are designed to detect
different groups of compounds, including alcohols,
ketones, and low-pressure gases. The ‘headspace’ (the
air above a sample) is injected into the sensor array
and each sensor response is unique. A typical feature
of this response is then extracted and used to train
the instrument with a pattern recognition algorithm,
therefore allowing the instrument to be trained to
recognise a range of conditions [16]. Although most
of the papers reviewed below use this technique,
there are obvious limitations with using an eNose
for screening purposes. Sensor sensitivity ranges from
1 part per million to 1 part per billion, which is
less sensitive than the detection limit of GC–MS and
limited data is available on the effect of multiple
compounds on detection limits (also a factor which
does not affect GC–MS measurements). Sensitivity
of sensors can be increased by selective coatings, but
this requires prior knowledge of volatile biomark-
ers [17]. The discriminatory power of sensor arrays
depends on the number of sensors and their differ-
ence in affinity and is still limited compared to the
resolution of GC separation and specificity of GC
and MS data combined. Finally, eNoses do not allow
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identification of single compounds and cannot point
to the underlying metabolic processes.
Electronic nose technology has been further
developed since its inception, and now covers tech-
niques including ion mobility spectrometry (IMS),
proton transfer reaction mass spectrometry (PTR-
MS), GCs employing gas sensors as the detector and
optical gas spectrometer instruments, all of which can
be configured to give a rapid result within 60 s. IMS
and PTR-MS technology generally offers the highest
sensitivity of these newer systems and has been fur-
ther refined as field asymmetric ion mobility spec-
troscopy (FAIMS). FAIMS shows even greater sens-
itivity, as it can track the movements of a single ion
through an electrical field and can detect minute
changes in the composition of VOCs [18]. Potentially,
these methods can be utilised in neonates when spe-
cific disease predictors are identified.
Selected ion flow tube mass spectrometry (SIFT-
MS) is a newer technology that allows for real-time
absolute quantification of several trace gases simul-
taneously, even when an abundance of atmospheric
gas is present. VOCs are ionised and reacted with pre-
cursor ions and fed into a mass spectrometer which
detects precursor and traces gas ions, allowing for
identification and quantification of VOCs present in
the sample [19]. All direct inlet methods (IMS, PTR-
MS, FAIMS and SIFT), however, analyse the entire
mixture and rely on sufficient discrimination in mass
and the (limited) degree of fragmentation for identi-
fication of VOCs. They all use soft ionisation meth-
ods, which reduce the number of ions but at the same
time do not produce mass spectra that can be com-
pared to existing librariesmaking identificationmuch
more difficult especially in the absence of any reten-
tion data.
In summary, powerful chemical analysis tech-
niques are available for the detection of VOCs
in human samples. Highly sensitive methods like
GC–MS are ideally suited for the identification and
quantification of minute quantities of compounds,
which are useful for the detection of biomarkers for
specific diseases and ideally preferred for neonatal
populations where the concentration of VOCs is
expected to be low and disease predictors are as
yet unknown. Newer technology like SIFT-MS can
be used to for the clinical implementation of these
identified biomarkers on patients and for real-time
measurements.
3. Methods for the literature review
Using a combination of keywords, medical
subject headings and Boolean combinations,
six databases were searched for papers and
abstracts on VOCs in neonates (supplement-
ary information, which is available online at
stacks.iop.org/JBR/15/024002/mmedia). Full-text
articles were reviewed from an initial shortlist which
was chosen based on the title and abstract. Further
manual searches in the bibliography of the chosen
papers were undertaken for any further relevant art-
icles which were not included in the earlier searches.
For studies in adults and children, the following
combination of terms were used to search review
papers which were used to identify references to
original studies: volatile organic compound, VOC,
exhaled breath condensate, breath biomarker, chronic
obstructive pulmonary disease, COPD, asthma, respir-
atory infections, pulmonary, gas chromatography mass
spectrometry, GCMS, child, children, adult, systematic
review.
4. VOCs in neonates: stool, breath, and
urine
The systematic search revealed 13 original papers on
VOCs in neonates (10 full-text papers and 3 confer-
ence abstracts) and 11 review articles. In addition,
four full-text articles were identified which explored
the composition of VOCs in the neonatal environ-
ment. Details of the filtering of studies at various
stages are presented in figure 1. Manual searches
in the references of the papers failed to identify
any further original studies. A list of the selected
papers is presented in table 1 and a summary of
the literature is presented below categorised by the
sample used in the study. Despite VOCs having
been extensively studied in adults, there have been
relatively fewer studies in the neonatal population.
Most studies have examined the use of VOCs in
faecal samples; however, there is some data available
examining VOCs detectable in respiratory and urine
samples.
4.1. VOCs in neonatal stool
VOCs in neonatal faecal samples have been the most
extensively studied for potential diagnostic abilities.
Faecal VOCs have been studied as biomarkers for
a range of conditions including necrotising entero-
colitis (NEC), bronchopulmonary dysplasia (BPD)
and late-onset neonatal sepsis (LONS).
Berkhout et al examined faecal VOCs in a cohort
of infants born at <30 weeks’ gestational age, tak-
ing daily faecal samples for the first 28 d of life and
examining them with a commercially available eNose
device. Infants born in three centres in the Nether-
lands were recruited. They demonstrated that faecal
VOC profiles show a significant difference up to 3 d
before the onset of clinical symptoms of late-onset
sepsis in 127 infants and matched controls without
indwelling percutaneous central venous or arterial
access [20]. This is particularly true for LONS caused
by Staphylococcus aureus and Escherichia coli, whereas
infections caused by coagulase-negative staphylococ-
cus species did not seem to alter faecal VOCs signi-
ficantly [21], suggesting that LONS may be related
to altering intestinal conditions and translocation of
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Figure 1. Flowchart showing search results and filtering of articles.
bacterial species to the bloodstream. Berkhout et al
have also demonstrated that in this same cohort, BPD
could be predicted with up to 70% accuracy by the
changing faecal VOC profile from day 14 of life in
a small group of 15 infants with matched controls
[22]. However, the eNose detector is not designed
to identify specific compounds thus the metabolic
processes involved for these differences could not be
identified.
Understandably, most attention has been given to
the ability of faecal VOCs to act as biomarkers for
developing NEC due to easy access to the sample.
de Meij et al [23] examined faecal VOCs (also using
an eNose) from infants in the Berkhout et al cohort
described above, to determine whether VOCs altered
before the onset of clinical symptoms. VOC profiles
from 13 infants with Bell’s Stage II or higher NEC
were compared with 31 infants who developed sepsis
and 14 matched healthy controls. They demonstrated
that NEC could be discriminated with increasing
accuracy from controls in each of the 5 d leading up
to clinical symptoms of the disease, with 65% accur-
acy five days before and 99% accuracy one day before.
Additionally, faecal VOC profiles could be reliably
differentiated between those infants developing sepsis
and those developing NEC 2 to 3 d prior to onset of
clinical symptoms.
A multi-centre study from eight UK neonatal
units has examined faecal samples taken from 1326
infants born at 23–34 weeks’ gestation using head-
space GC–MS. The group identified 224 different
VOCs present in their pilot work, with the number
of VOCs present increasing as the infants matured,
with the possibility of detecting changes several days
before symptom-onset [24, 25]. Overall, when the
entire cohort was analysed, a broad range of VOCs
was found in 32 babies who developed NEC Stage
IIa or higher, with three groups of VOCs including
aldehydes, butanoic acid andmethanedithiones being
strongly associated with an increased risk of NEC.
All these factors were also associated with increas-
ing postmenstrual age thus may reflect the presence
of species in the maturing gut microbiome. Cer-
tain VOCs were also found to play a protective role
against development of NEC including 3-methyl and
2-methylbutanoic acid. These changes in VOCs could
be seen up to 4 d before the onset of clinical symptoms
[26].
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Table 1. Details of included studies on neonatal patients.
Study ID Berkhout et al (2017)
Title Detection of sepsis in preterm infants by fecal volatile organic compounds analysis:
a proof of principle study
Year 2017
Population Sevnty-six preterm infants (<30 weeks’ gestation); 36 with late onset sepsis, 40
matched controls
Sample type Faeces
Method of detection eNose (Cyranose 320)
Study ID Berkhout et al (2018)
Title Development of severe broncho-pulmonary dysplasia is associated with alterations
in fecal volatile organic compounds.
Year 2018
Population Thirty preterm infants (<30 weeks’ gestation); 15 with BPD, 15 matched controls
Sample type Faeces
Method of detection eNose (Cyranose 320)
Study ID Berkhout et al (2019)
Title Late-onset Sepsis in preterm infants can be detected preclinically by fecal volatile
organic compound analysis: a prospective, multicenter cohort study.
Year 2019
Population Two hundred and fifty-four preterm infants (<30 weeks’ gestation); 127 with late
onset sepsis; 127 matched controls
Sample type Faeces
Method of detection Field asymmetric ion mobility spectroscopy
Study ID Berkhout et al (2020)
Title Preclinical detection of non-catheter related late-onset sepsis in preterm infants by
fecal volatile compounds analysis.
Year 2020
Population Forty-nine preterm infants (<30 weeks’ gestation); 24 with late onset sepsis, 25
matched controls
Sample type Faeces
Method of detection Field asymmetric ion mobility spectroscopy
Study ID Cordell et al (2013)
Title GC-MS analysis of ethanol and other volatile compounds in micro-volume blood
samples–quantifying neonatal exposure.
Year 2013
Population Two hundred and eighty-nine samples from neonatal population
Sample type Blood
Method of detection Gas chromatography–mass spectrometry
Study ID deMeij TG et al (2015)
Title Early detection of necrotizing enterocolitis by fecal volatile organic compounds
analysis.
Year 2015
Population Fifty-eight preterm infants (<30 weeks’ gestation); 13 NEC, 31 sepsis, 14 matched
controls
Sample type Faeces
Method of detection eNose (Cyranose 320)
Study ID El Manouni et al (2018)
Title Fecal volatile organic compounds in preterm infants are influenced by enteral
feeding composition.
Year 2018
Population Thirty preterm infants (<30 weeks’ gestation)
Sample type Faeces
Method of detection eNose (Cyranose 320)
Study ID El-Metwally et al (2018)
Title Urinary metabolites of volatile organic compounds of infants in the neonatal
intensive care unit.
Year 2018
Population Eighty preterm infants (<37 weeks’ gestation)
Sample type Urine
Method of detection Ultra-high-performance liquid chromatography coupled with electrospray
ionization tandem mass spectrometry
(Continued)
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Table 1. (Continued.)
Study ID Garner et al (2009)
Title Analysis of faecal volatile organic compounds in preterm infants who develop
necrotising enterocolitis: a pilot study
Year 2009
Population Thirteen infants <36 weeks’ gestation; 6 who developed NEC, 7 matched controls
Sample type Faeces
Method of detection Gas chromatography-mass spectrometry
Study ID Mayor et al (2014)
Title Paediatric Faecal VOC analysis: method optimisation.
Year 2009
Population One hundred and four preterm infants (23–34 weeks’ gestation); 34 developed
NEC, 70 matched controls
Sample type Faeces
Method of detection Gas chromatography–mass spectrometry
Study ID Merchant et al (2014)
Title Analysis of exhaled volatile organic compounds (VOC) in intubated preterm
infants.
Year 2014
Population Five infants; 3 preterm (2 with RDS, 1 with respiratory failure), 2 controls
Sample type Exhaled breath (sampled from expiratory limb of ventilator circuit)
Method of detection Gas chromatography–mass spectrometry
Study ID Meyer-Monath et al (2014)
Title Analysis of BTEX and chlorinated solvents in meconium by headspace-solid-phase




Method of detection Gas chromatography–mass spectrometry
Study ID Prazad et al (2008)
Title Airborne concentrations of volatile organic compounds in neonatal incubators.
Year 2008
Population Ten unoccupied incubators
Sample type Air
Method of detection Gas chromatography–mass spectrometry
Study ID Probert et al (2019)
Title Faecal volatile organic compounds in preterm babies at risk of necrotising
enterocolitis: the DOVE study.
Year 2019
Population One hundred and two infants <34 weeks’ gestation; 32 developed NEC, 70
matched controls
Sample type Faeces
Method of detection Gas chromatography–mass spectrometry
Study ID Rogosch et al (2014)
Title Detection of bloodstream infections and prediction of bronchopulmonary
dysplasia in preterm neonates with an electronic nose.
Year 2014
Population Twenty-eight intubated preterm infants
Sample type Tracheal aspirates
Method of detection eNose (Cyranose 320)
Study ID Steinbach et al (2019)
Title Bedside measurement of volatile organic compounds in the atmosphere of
neonatal incubators using ion mobility spectrometry.
Year 2019
Population Seventeen incubators occupied by preterm infants; 9 unoccupied incubators
Sample type Air
Method of detection Ion Mobility Spectrometry
4.2. VOCs in neonatal respiratory samples
Despite a move towards less invasive respiratory sup-
port for premature infants, a significant proportion
continue to require intubation and mechanical vent-
ilation during their management. Therefore, exhaled
gases, tracheal aspirates and bronchoalveolar lav-
age samples provide a source of VOCs for potential
point-of-care diagnostics. To date, only two studies
have examined VOCs in samples from the lungs of
neonates.
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A pilot study published as a conference abstract
of two preterm neonates ventilated for respiratory
distress syndrome (RDS) examined VOCs from gas
obtained from the expiratory limb of a ventilator cir-
cuit, using gas chromatography. These were com-
pared to samples obtained from two term infants
electively ventilated for surgery, and one preterm
infant ventilated for respiratory failure secondary to
congenital hypotonia. They found a total of 79 VOCs
present in the samples including carbon monox-
ide and dioxide, methane, and a wide variety of
nonmethane hydrocarbons, halogenated gases, alkyl-
nitrates, selected sulphur and oxygen compounds.
Seven gases were identified that showed a possible
trend towards being higher in those infants with RDS,
of particular note was chloroform which was three
times more abundant [27].
The single centre study by Rogosch et al [28]
examined tracheal aspirates obtained by lavage and
suction from 28 intubated preterm infants using an
eNose system. They found that the eight infants in
their cohort with a confirmed bloodstream infection
could be differentiated on ‘smell print’ analysis. They
also found a non-significant trend towards being able
to differentiate those infants with BPD compared to
those without. These studies show the potential of
detecting VOCs in neonates to diagnose and guide
monitoring of specific diseases.
4.3. VOCs in neonatal urine
There have been several papers examining the detec-
tion of peptide compounds in urine to assist with
the early diagnosis of NEC [29], but very little atten-
tion has been paid to examining VOCs in urine
for early diagnostics. A study by El-Metwally [30]
compared VOC metabolites in the urine of pre-
term infants nursed in incubators compared to open
cots using ultra-high-performance liquid chroma-
tography coupled with electrospray ionization tan-
dem MS. They demonstrated that detecting these
metabolites was possible and that there was a sig-
nificant difference in the VOC metabolites between
incubator- and cot-nursed infants. Their study,
although small, suggested that preterm infants nursed
in incubators may absorbmore VOCs associated with
tobacco smoke, plasticizers from medical devices,
excipients used in medications, and cleaning/steriliz-
ing agents used in the environment.
4.4. VOCs related to the neonatal environment
In a single-centre study, Steinbach et al [31] meas-
uredVOCs in 9 occupied and 17 unoccupied neonatal
incubators (all preterm infants) using ion-mobility
spectrometry. The authors were successful in identi-
fying discriminating VOC profiles from occupied and
unoccupied incubators using principal component
and decision tree analysis. They concluded that pre-
term infants produce identifiable VOC profiles in
their environment which can potentially be useful for
diagnostic purposes.
In variable temperature, humidity and air-
circulation conditions, Prazad et al [32] used GC–MS
to measure VOCs from unoccupied neonatal incub-
ators attempting to identify their exposure to poten-
tially harmful incubator-generated VOCs. Increased
concentration of two compounds, 2-heptanone and
n-butyl acetate, were found in the incubators com-
pared to ambient air. The concentration of both
increased significantly in temperature and humid-
ity conditions typical of the preterm neonatal envir-
onment. This study raises important further ques-
tions regarding exposure of vulnerable neonates to
environmental VOCs and xenobiotics. In addition,
their results also suggest that any future work on
neonatal samples will need further control samples
from their environment to differentiate between
metabolic products from the patient or from envir-
onmental exposure.
A study by Meyer-Monath et al [33] attemp-
ted to identify fetal exposure to benzene, toluene,
ethylbenzene, o-m-p-xylene, trichloroethylene and
tetrachloroethylene by analysing the headspace of
meconium using GC–MS. Sensitivity was further
increased by using headspace-solid-phase microex-
traction steps prior to actual measurement, and the
steps involved were optimised for the purpose.
To determine exposure of neonates to ethanol
excipient containing medications, Cordell et al [34]
successfully demonstrated the identification of sev-
eral VOCs from small volume blood samples from
neonatal patients. The authors plan to use this sys-
tem to identify the course of ethanol metabolism in
neonates receiving ethanol containing medications.
While this paper demonstrates the sensitivity of the
GC–MS method to detect individual VOCs, using
blood-samplesmakes it an invasive process. However,
they established that similar methods could be used
on non-invasive samples from patients for identifica-
tion and quantification of individual VOCs.
5. Limitations of current methods
There are many challenges to implementing current
methods of VOC analysis into routine, point-of-care
clinical use for diagnostic purposes.
There is evidence that VOC composition is altered
by enteral feeding regimens in neonates. A study by
El Manouni El Hassani et al studied 15 infants of
<30 weeks’ gestational age who were fed >75% either
maternal or donor expressed breast milk comparing
their faecal VOC profiles to infants who were fed
>75% formula milk, with stable diets over the first
28 d of life. Again, an eNose detector was used to
identify VOC profiles. Although the numbers studied
were small, they found a significant difference inVOC
profiles over the first 21 d of life [35]. This presents
a challenge to the use of devices such as the eNose,
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which does not identify VOCs present but gives an
overview of the VOC mix present in a sample. Pre-
term infants on neonatal units are often fed a broad
mix of diets, dependent onmaternal and donor breast
milk availability and unit preferences about preterm
formula milk use and brand. This study suggests that
feeding variables also need to be recorded in stud-
ies on VOCs as they can affect the interpretation
results.
As demonstrated by El-Metwally [30], the link
between VOCs measures and their potential role as
a disease biomarker may be confounded by differen-
tial environmental exposures or pre-emptive thera-
peutic interventions. Preterm infants in particular are
at high risk of absorbing environmental compounds,
and have immature secretory and excretory pathways.
It has been demonstrated that the atmosphere within
unoccupied incubators has detectable levels of VOCs
which are also influenced by the temperature and
humidity settings of the incubator [32]. The effect
this has on infants is as-yet unclear. Additionally,
excipients in medications, typically ethanol, also con-
tain VOCs which are detectable in the bloodstream of
those infants receiving them [34]. There is also evid-
ence that trans-placental passage of VOCs occurs in-
utero as they can be detected in themeconiumof new-
born infants [33]. In this work we have not reviewed
the causal pathways for the breadth of work identi-
fied, and some encouraging resultsmay turn out to be
due to xenobiotic exposures (exogenous to the infant)
rather than endogenous metabolites.
These observations highlight the potential vari-
ations in VOCs between individual infants depending
on their antenatal history, previous and current man-
agement and NICU environment, and it is unclear
whether different forms of biological samples stud-
ied may all be affected. It is also unclear if VOC levels
are stable or vary in the same individuals over time.
Studies examining repeatability of VOC examination
in adults with stable COPD have shown variation in
profiles on measurements taken on the same day and
over a 7 d period [36] and similarly for profiles in
healthy and asthmatic children [37]. The repeatab-
ility of VOC measurements is unknown in healthy
neonates, nor how disease states may impact on the
reproducibility of profiles. This may all lead to fur-
ther complicating the interpretation of VOC patterns
and profiles in the early stages of the disease.
Many of the techniques employed in these stud-
ies are unable to give a real-time assessment of
VOC profiles in a clinical setting, and several meth-
ods employed, particularly GC–MS methods and its
derivatives, require laboratory processing time. This
can limit the clinical applicability of VOCs for early
disease detection, as if the VOC profile changes a few
days before symptom onset, but sample processing
takes longer than this time, there can be no early
disease detection and patient benefit. Newer VOC
detection technologies as described above can give
rapid real-time results but are largely untested in the
neonatal population.
Thus, there are only a few studies of VOCs in
neonates, often with a small number of infants and
sometimes from the same cohort. However, these
studies should be considered as proof of principle
showing promise for studying thesemethodologies in
larger longitudinal cohorts of newborn infants with
specific conditions such as NEC, sepsis, and BPD.
In addition to the issues of prediction and validity,
any potential test requires implementation at, or near,
the neonatal unit; and a rapid enough result to help
guide the clinician. For somemeasures this lag maybe
acceptable in the region of hours or even days (e.g. the
development of chronic lung disorders where results
may guide long term ventilation of respiratory sup-
port strategies), while other diseases processes pro-
gress much faster and require rapid turn-around to
be of clinical use (e.g. developing infections).
6. Lessons from studies in adults and
children
Adult and paediatric studies on the use of VOCs as
disease predictors can provide useful direction while
setting up similar research programmes for neonatal
patients. The literature on adult VOCs is vast and only
a few examples are presented belowwhichmay poten-
tially guide future research studies in neonates.
6.1. Examples of VOC studies in adults
Boots et al [38] describes detection of pulmonary
bacterial infections by detection of VOCs in exhaled
air. Four different microorganisms (E. coli, Pseudo-
monas aeruginosa, S. aureus and Klebsiella pneumo-
niae) were analysed by GC–MS with 25 VOCs being
identified as being differently profiled across the vari-
ous microorganisms. Additionally, for S. aureus, anti-
biotic sensitive and resistant strains were shown to
have different VOC profiles. Kamal et al [39] report
the results of a study that employed GC–MS to distin-
guish between viral and bacterial infections in chronic
obstructive pulmonary disease (COPD) patients. Pre-
liminary findings from COPD patients identified 14
increased VOCs in patients with positive bacterial
sputumcultures. As exhaled breath condensate (EBC)
is an easily accessible source of sample in the neonatal
population, who are prone to infection and pneumo-
nia, these results could guide research in neonates for
early detection of pulmonary infection.
Determination of a set of COPD breath marker
molecules has been underway for some years but the
results are generally inconsistent. This is typified by
Christiansen et al [40] who report a systematic review
of work done to identify potential COPD breath
marker molecules. Twelve papers were included, but
no consistent markers were found with only three
markers reported in more than one study. Recently,
Besa et al [41] reported the results of a VOC study
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of 45 COPD patients with 51 healthy controls. One
hundred and thirty-seven VOCs were found to have a
statistically significant difference between the COPD
and healthy groups. Six of these VOCs when com-
bined were found to correctly discriminate COPD
patients from healthy controls with an accuracy of
70%.Allers et al [42] describes a studywhere two vari-
ations on GC–MS devices were employed to invest-
igate correlations between VOCs and COPD with
smoking taken into account, and successfully identi-
fied four distinct VOCs in total that showed statist-
ically significant differences between healthy controls
and patients with COPD. In summary, VOCs from
breath samples in adults can be used as biomarkers of
disease, an approach which is potentially replicable in
the neonatal population who develop inflammatory
conditions of the lungs like BPD [43].
Hayton et al [44] conducted a systematic review
of studies investigating breath predictors of idiopathic
pulmonary fibrosis. Of the 14 included studies, a total
of 20 VOCs that distinguished pulmonary fibrosis
from controls were identified with three identifying
alveolar nitric oxide as significantly higher in cases
than controls. Lamote et al [45] describe a cross-
sectional case-control study that identified (and con-
firmed earlier work) discriminating VOCs as pre-
dictors of malignant pleural mesothelioma. Using
a GC–MS supplied by Markes (Markes Interna-
tional Ltd, Llantrisant, UK), the following VOCs
were identified as discriminatory: nonanal, diethyl
ether, limonene, methyl cyclopentane, cyclohex-
ane, and isothiocyanatocyclohexane. These high-
sensitivity systems would be useful for the discovery
of predictors in the neonatal population before assess-
ing them as disease markers.
6.2. Examples of VOC studies in children
In children, primarily exhaled breath but also faecal
VOC profiling are reported, with asthma the fre-
quent reason for profiling of exhaled breath. Exhaled
breath of 252 preschool children were analysed using
GC–MS in a study that found 17 VOCs within
3256 identified different compounds that discrim-
inated preschool asthmatic children from transient
wheezing children [46] with a prediction success
rate of 80% in terms of the correct medical dia-
gnosis. Another study analysed the exhaled breath
of 64 participants, aged 6–18 years and used the
medical diagnosis of asthma within the children
to construct models around the measured VOCs
that were able to significantly distinguish between
those who had and did not have asthma and there-
fore identify those in need of corticosteroid therapy
[47]. Ehrmann et al [48] split 82 children into con-
trols, asthmatics, and those with either episodic viral
wheeze (EVW) or multiple-trigger wheeze (MTW).
Following analysis by GC–MS, they found 20 VOCs
to differ between asthmatics and controls, and 13
VOCs to differ between EVW and MTW. Schee
et al investigated the distinction between rhinovirus-
inducedwheeze andnon- rhinovirus-inducedwheeze
as its presence is associated with increased risk of
asthma. The VOC profile they found was able to
discriminate wheeze from non-wheeze, but this dis-
tinction only persisted after symptomatic recovery
for the rhinovirus-induced wheeze [49]. Mastrigt
et al [50] compared exhaled breath samples from
healthy children aged 6–18 years, with those from
children with asthma or cystic fibrosis (CF). The
study failed to produce a profile that could distin-
guish asthma from CF but did find a profile that dis-
tinguished healthy from asthmatic and CF separately.
The above examples suggest that EBC are a ready
source of sample for research, which can be used in
neonates for monitoring evolving lung infection or
inflammation.
7. Future directions
VOCs have been successfully identified and quanti-
fied as biomarkers in research studies from all age
groups, although significant variation on results and
use of different methods limit their clinical imple-
mentation. In neonates, only a limited number of
studies have attempted to use VOCs as predictors
of disease using cross-sectional sampling methods
from small cohorts. Due to their potential benefits
including non-invasive sampling methods, real-time
sampling and detection of an evolving disease pro-
cess, further studies on VOCs are recommended in
the future. These studies should collect longitudinal
samples from an appropriate cohort of infants and
use highly sensitive methods for the detection and
quantification of VOCs to identify potential predict-
ors of disease in neonates. EBCs from ventilated and
unventilated neonates remain understudied, partly
due to technical difficulties with sample collection
from small infants [51]. Integrated systems like the
‘Pneumopipe’ developed for adults [37, 52] could be
applied in neonates and small infants to aid in collec-
tion and analysis of EBC from this population group.
Careful repeatability and validation of results from
further studies will be essential before VOCs can be
considered for clinical use in patient populations.
8. Conclusion
VOCs in bodily fluids contain important profiles of
metabolic activity and disease-related changes. These
profiles can be detected in a variety of samples includ-
ing breath, urine, stool, saliva, sweat and blood. The
biggest attraction of this area of research is that in
spite of the mostly non-invasive nature of the sample
collection, these metabolic signatures can be detected
in minute quantities and have already been shown to
be able to differentiate adequately between health and
disease.
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In neonates, research into VOCs is particularly
attractive due to the non-invasive sample collec-
tion techniques, non-interference with the neonatal
physiology and the potential ability to identify bio-
markers for several longitudinal disease processes. So
far, only one study has attempted to look at stool in
enough detail to identify and quantify metabolic bio-
markers for disease. Other studies have usedmethods
which have only attempted to differentiate between
patient groups without being able to identify under-
lying metabolic processes. Clearly, to be successful as
a strategy for diagnostic and prognostic purposes, an
understanding of the metabolic processes and robust
validation as a biomarker would be required for the
identification of potential therapeutic pathways. Fur-
ther research is required in appropriate patient groups
using detailed longitudinal sampling of breath, urine
and stool for identification and quantification of
VOCs as biomarkers of neonatal disease.
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